Triple-negative breast cancer

Wiener Medizinische Wochenschrift

Volumn 160, Issue 7-8, 2010, Pages 174-181

  Bartsch, Rupert ^a,b   Ziebermayr, Reinhard ^b   Zielinski, Christoph C ^a   Steger, Guenther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Elisabethinen Teaching Hospital   (Austria)

Author keywords

Basal like breast cancer; Bevacizumab; Gene expression profiles; PARP; Triple negative disease

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BSI 201; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; E 2100; EPIRUBICIN; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; NAVELBINE; OLAPARIB; PACLITAXEL; SORAFENIB; SUN 1064; SUNITINIB; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DRUG DOSE REGIMEN; FATIGUE; HAND FOOT SKIN TOXICITY; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; NAUSEA AND VOMITING; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RISK FACTOR; SKIN TOXICITY; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DNA DAMAGE; DNA REPAIR; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 77954633734     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-010-0773-6     Document Type: Article

References (53)

1. American Cancer Society Facts and Figures. Available via: http://www.cancer.org/downloads/STT/Global-Facts-and-Figures-2007-rev2.pdf. Cited September 21st 2009.
2. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast cancer. Nature, 406: 747-752, 2000.
3. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 100: 8418-8423, 2003.
4. Nielson TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Mod Pathol, 19: 264-271, 2006.
5. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res, 14: 1368-1376, 2008.
6. Rakka EA, Tan DS, Foulkes WD, et al. Are triple-negative tumours and basal-like breast cancer synonymous? Breast Can Res, 9: 404, 2007.
7. Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohistochemistry can refine prognosis in triple negative breast cancer. BMC Cancer, 7: 134, 2007.
8. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst, 95: 1482-1485, 2003.
9. Futreal PA, Liu Q, Shattuk-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science, 266: 120-122, 1994.
10. Turner NC, Reis-Filho JS, Russel AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene, 26: 2126-2132, 2007.
11. Berger C, Pierce LN, Kruger M, et al. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci USA, 98: 130-135, 2001. (Pubitemid 32095875)
12. Turner N, Tutt A, Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer, 4: 814-819, 2004.
13. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene, 25: 5854-5863, 2006.
14. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA-repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434: 917-921, 2005.
15. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295: 2492-2502, 2006.
16. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression- based predictors for breast cancer. N Engl J Med, 355: 560-569, 2006.
17. Beslija S, Bonneterre J, Burstein H, et al. Third Consensus on medical treatment of metastatic breast cancer. Ann Oncol, 20: 1771-1785, 2009.
18. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13: 4429-4434, 2007.
19. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer, 110: 876-884, 2007.
20. Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol, 37: 1217-1226, 2006.
21. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat, 109: 123-139, 2998.
22. Liedtke C, Manzouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 26: 1275-1281, 2008.
23. Steger GG, Galid A, Gnant M, et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol, 25: 2012-2018, 2007.
24. Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med, 2: 72-79, 1996.
25. Chabalier C, Lamare C, Racca C, et al. BRCA1 downregulation leads to premature inactivation of spindel checkpoint and confers paclitaxel resistance. Cell Cycle, 5: 1001-1007, 2006.
26. Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapyin triple-negative breast cancer. Ann Oncol, 19: 1847-1852, 2009.
27. Available via: http://www.clincialtrials.gov. Cited October 21st 2009.
28. Frasci G, Comella P, Rinaldo M, et al. Preoperative weekly cisplatinepirubicin-paclitaxel with G-CSF support in triple-negative operable breast cancer. Ann Oncol, 20: 1185-1192, 2009.
29. Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat, 115: 359-363, 2009.
30. Diallo-Danebrock R, Ting E, Guz O, et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res, 13: 488-497, 2007.
31. Folkman J, Klagsbrun M. Angiogenic factors. Science, 235: 442-447, 1987.
32. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab and capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol, 23: 792-799, 2005.
33. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell, 8: 299-309, 2005.
34. Miller KD, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 357: 2666-2676, 2007.
35. Miles D, Chan A, Romieu G, et al. Randomised, double-blind, placebo-controlled phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer: AVADOJ Clin Oncol, 26(Suppl 18): 1008S, 2008.
36. Pivot X, Verma S, Thomsen C, et al. Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study. J Clin Oncol, 27(Suppl 15): 64S, 2009.
37. Robert N, Dieras V, Glaspy J, et al. RIBBON-1: a randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer. J Clin Oncol, 27(Suppl 15): 42S, 2009.
38. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res, 15: 5020-5025, 2009.
39. Lee JB, Woo OH, Park KH, et al. Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Invest New Drugs, 2009. [Epub ahead of print]
40. Brufsky A, Bondarenko IN, Smirnov V, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res, 69(Suppl. 3): Abstract Nr 42, 2009.
41. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol, 26: 1810-1816, 2008.
42. Moreno-Aspitia A, Morton RF, Hillman DW, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol, 27: 11-15, 2009.
43. Baselga J, Segalla JG, Roche H, et al. 3LBA SOLTI-0701: A double- blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC). Eur J Cancer, 7(Suppl 2): 3S-4S, 2009.
44. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol, 27(Suppl 18): 803S, 2009.
45. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol, 27(Suppl 15): 793S, 2009.
46. Hoadley KA, Weigman VJ, Fan C, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics, 8: 258, 2007.
47. Carey LA, Rugo H, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple negative (basal-like) breast cancer. J Clin Oncol, 26(Suppl 15): 43S, 2008.
48. Cristofanilli M, Valero V, Mangalik A, et al. A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). J Clin Oncol, 26(Suppl 15): 44S, 2008.
49. O'Shaughnessy J, Weckstein D, Vukelja S, et al. Randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat, 106(Suppl 1): 22S-23S, 2007.
50. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol, 26: 5544-5552, 2008.
51. Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol, 2009. [Epub ahead of print]
52. Ozaki K, Kishikawa F, Tanaka M, et al. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci, 99: 376-384, 2008.
53. Marty B, Maire V, Gravier E, et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res, 10: R101, 2008.